MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Epirubicin (Ellence)

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021

Cancer. 2008 Jan 25 [Epub ahead of print] [Link] Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM Jr, Soori GS, Nikcevich DA, Kardinal CG, Northfelt DW, Adjei AA. Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota. Abstract Background: The North Central Cancer Treatment Group (NCCTG) conducted a […]

Comments Off on A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021

Chemotherapy in malignant pleural mesothelioma

Revista Portuguesa de Pneumologia. 2005 Nov;11(6 Suppl 1):14-5. [Link] Barata F, Cortesao N, Marques A, Figueiredo A. Servico Pneumologia Centro Hospitalar de Coimbra. Abstract Rational and objective: During the last few years a variety of new chemotherapy agents have been used (mostly in combination) in the treatment of malignant pleural mesothelioma (MPM). Combination therapy with […]

Comments Off on Chemotherapy in malignant pleural mesothelioma

Chemotherapy in malignant pleural mesothelioma

Revista Portuguesa de Pneumologia. 2005 Nov-Dec;11(6 Suppl 1):14-5. [Link] F B, N C, A M, A F. Servico Pneumologia Centro Hospitalar de Coimbra. Abstract Rational and objective: During the last few years a variety of new chemotherapy agents have been used (mostly in combination) in the treatment of malignant pleural mesothelioma (MPM). Combination therapy with […]

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

Lung Cancer. Volume 50, Issue 1, October 2005, Pages 75-82. Available online June 13, 2005. [Link] T. Berghmansa, J.J. Lafitteb, M. Paesmansc, B. Stachd, M.C. Berchiere, P. Wackenierf, J. Lecomteg, T. Collonh, P. Mommeni, J.P. Sculiera and For the European Lung Cancer Working Party (ELCWP)1 aDepartment of Intensive Care and Thoracic Oncology, Institut Jules Bordet, […]